Advaxis, Inc. (ADXS) financial statements (2021 and earlier)

Company profile

Business Address 305 COLLEGE ROAD EAST
PRINCETON,, NJ 08540
State of Incorp. DE
Fiscal Year End October 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:3325324471152112
Cash and cash equivalents332532442411367
Short-term investments     3946
Other undisclosed cash, cash equivalents, and short-term investments    47  
Restricted cash and investments   1   
Receivables    432
Prepaid expense     10
Deferred costs2222341
Other current assets     00
Other undisclosed current assets11133  
Total current assets:3628365081160115
Noncurrent Assets
Operating lease, right-of-use asset55 
Property, plant and equipment2247741
Intangible assets, net (including goodwill)3355543
Intangible assets, net (excluding goodwill)3355543
Other noncurrent assets0000000
Total noncurrent assets:10119121295
TOTAL ASSETS:4639456294169120
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3241214134
Accounts payable0016521
Accrued liabilities22369113
Deferred revenue and credits715 
Other liabilities  000  
Other undisclosed current liabilities11011 00
Total current liabilities:4352321284
Noncurrent Liabilities
Long-term debt and lease obligation55     
Operating lease, liability55 
Liabilities, other than long-term debt  111 0
Other liabilities  111  
Derivative instruments and hedges, liabilities      0
Other undisclosed noncurrent liabilities(5)(5) 141722 
Total noncurrent liabilities:5511519220
Total liabilities:8863839504
Stockholders' equity
Stockholders' equity attributable to parent3830402454119116
Common stock0000000
Treasury stock, value     (0)(0)
Additional paid in capital452441424392355327250
Accumulated deficit(415)(411)(384)(368)(301)(208)(134)
Total stockholders' equity:3830402454119116
TOTAL LIABILITIES AND EQUITY:4639456294169120

Income statement (P&L) ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
Revenue, net124 
Gross profit:20216124 
Operating expenses(24)(27)(39)(76)(111)(80)(49)
Operating loss:(23)(26)(18)(70)(99)(76)(49)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(0)(0)(0)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes  14100
Loss from continuing operations before equity method investments, income taxes:(23)(26)(17)(66)(98)(76)(49)
Other undisclosed income (loss) from continuing operations before income taxes(0)0     
Loss from continuing operations before income taxes:(23)(26)(17)(66)(98)(76)(49)
Income tax expense (benefit)(0)(0)(0)(0)432
Net loss available to common stockholders, diluted:(23)(26)(17)(67)(93)(74)(47)

Comprehensive Income ($ in millions)

1/31/2021
TTM
10/31/2020
10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
Net loss:(23)(26)(17)(67)(93)(74)(47)
Comprehensive loss, net of tax, attributable to parent:(23)(26)(17)(67)(93)(74)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: